Remember Me
Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:

OpenAIRE is about to release its new face with lots of new content and services.
During September, you may notice downtime in services, while some functionalities (e.g. user registration, login, validation, claiming) will be temporarily disabled.
We apologize for the inconvenience, please stay tuned!
For further information please contact helpdesk[at]openaire.eu

fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Jordan, RE; Adab, P; Sitch, A; Enocson, A; Blissett, D; Jowett, S; Marsh, J; Riley, RD; Miller, MR; Cooper, BG; Turner, AM; Jolly, K; Ayres, JG; Haroon, S; Stockley, R; Greenfield, S; Siebert, S; Daley, AJ; Cheng, KK; Fitzmaurice, D (2016)
Publisher: Elsevier
Languages: English
Types: Article
Subjects: R1
BACKGROUND: Many individuals with chronic obstructive pulmonary disease (COPD) remain undiagnosed worldwide. Health-care organisations are implementing case-finding programmes without good evidence of which are the most effective and cost-effective approaches. We assessed the effectiveness and cost-effectiveness of two alternative approaches to targeted case finding for COPD compared with routine practice. METHODS: In this cluster-randomised controlled trial, participating general practices in the West Midlands, UK, were randomly assigned (1:1), via a computer-generated block randomisation sequence, to either a targeted case-finding group or a routine care group. Eligible patients were ever-smokers aged 40-79 years without a previously recorded diagnosis of COPD. Patients in the targeted case-finding group were further randomly assigned (1:1) via their household to receive either a screening questionnaire at the general practitioner (GP) consultation (opportunistic) or a screening questionnaire at the GP consultation plus a mailed questionnaire (active). Respondents reporting relevant respiratory symptoms were invited for post-bronchodilator spirometry. Patients, clinicians, and investigators were not masked to allocation, but group allocation was concealed from the researchers who performed the spirometry assessments. Primary outcomes were the percentage of the eligible population diagnosed with COPD within 1 year (defined as post-bronchodilator forced expiratory volume in 1 s [FEV1] to forced vital capacity [FVC] ratio <0·7 in patients with symptoms or a new diagnosis on their GP record) and cost per new COPD diagnosis. Multiple logistic and Poisson regression were used to estimate effect sizes. Costs were obtained from the trial. This trial is registered with ISRCTN, number ISRCTN14930255. FINDINGS: From Aug 10, 2012, to June 22, 2014, 74 818 eligible patients from 54 diverse general practices were randomly assigned and completed the trial. At 1 year, 1278 (4%) cases of COPD were newly detected in 32 789 eligible patients in the targeted case-finding group compared with 337 (1%) cases in 42 029 patients in the routine care group (adjusted odds ratio [OR] 7·45 [95% CI 4·80-11·55], p<0·0001). The percentage of newly detected COPD cases was higher in the active case-finding group (822 [5%] of 15 378) than in the opportunistic case-finding group (370 [2%] of 15 387; adjusted OR 2·34 [2·06-2·66], p<0·0001; adjusted risk difference 2·9 per 100 patients [95% CI 2·3-3·6], p<0·0001). Active case finding was more cost-effective than opportunistic case finding (£333 vs £376 per case detected, respectively). INTERPRETATION: In this well established primary care system, routine practice identified few new cases of COPD. An active targeted approach to case finding including mailed screening questionnaires before spirometry is a cost-effective way to identify undiagnosed patients and has the potential to improve their health. FUNDING: National Institute for Health Research.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD 2015. Available from http://www.goldcopd.org
    • 2. ERS. European Lung White Book. Respiratory Health & Disease in Europe 2015. Available from: http://www.erswhitebook.org/
    • 3. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006, 28(3):523-32.
    • 4. Jordan R, Lam K-B, Cheng K, et al. Case finding for chronic obstructive pulmonary disease: a model for optimizing a targeted approach. Thorax 2010;65:492 - 98
    • 5. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive Lung Disease and Low Lung Function in Adults in the United States: Data From the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000, 160(11):1683-9.
    • 6. Buist AS, McBurnie M, Vollmer WM, et al, on behalf of the BOLD Collaborative Research Group. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet 2007, 370:741-50.
    • 7. British Lung Foundation. Invisible lives. Chronic obstructive pulmonary disease (COPD) - finding the missing millions. Available from: http://www lunguk org/Resources/British%20Lung%20Foundation/Migrated%20Resources/Documents/I/Invisible% 20Lives%20report pdf 2008.
    • 8. Department of Health. An outcomes strategy for people with chronic obstructive pulmonary disease (COPD) and asthma in England. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH_127974.
    • 9. COPD Foundation. http://www.copdfoundation.org/
    • 10. Haroon S, Jordan RE, O'Beirne-Elliman J, Adab P. Effectiveness of case-finding strategies for COPD in primary care: a systematic review and meta-analysis. npj Primary Care Respiratory Medicine 25, Article number: 15056 (2015) doi:10.1038/npjpcrm.2015.56
    • 11. Yawn BP, Duvall K, Peabody J. The Impact of Screening Tools on Diagnosis of Chronic Obstructive Pulmonary Disease in Primary Care. Am J Prev Med 2014;47(5):563-575)
    • 12. Jordan RE, Adab P, Jowett S et al. TargetCOPD: a pragmatic randomised controlled trial of targeted case finding for COPD versus routine practice in primary care: protocol. BMC Pulmonary Medicine 2014, 14:157. Available from: http://www.biomedcentral.com/1471- 2466/14/157
    • 13. Quality and Outcomes Framework. http://www.hscic.gov.uk/qof.
    • 14. Carter B and Hood K. Balance algorithm for cluster randomised trials. BMC Med. Res. Methodol., 2008, 8:65.
    • 15. National Institute for Health and Clinical Excellence: Chronic obstructive pulmonary disease : management of chronic obstructive pulmonary disease in adults in primary and secondary care. NICE clinical guideline 101, 2010. London: National Institute for Health and Clinical Excellence. Available from: www.guidance.nice.org.uk/cg101
    • 16. Miller MR, Hankinson J, Brusasco V, et al. ATS/ERS Task Force: Standardisation of spirometry. Eur Respir J 2005, 26(2):319-38.
    • 17. Hankinson JL, Eschenbacher B, Townsend M, Stocks J, Quanjer PH. Use of forced vital capacity and forced expiratory volume in 1 second quality criteria for determining a valid test. Eur Respir J 2015; 45: 1283-1292
    • 18. EQ-5D [http://www.euroqol.org/home.html]
    • 19. Quanjer PH, Stanojevic S, Cole TJ, et al and the ERS Global Lung Function Initiative: Multiethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012, 40:1324-1343. doi:10.1183/09031936.00080312.
    • 20. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-6.
    • 21. Haroon S, Adab P, Griffin C, Jordan R. Case finding for chronic obstructive pulmonary disease in primary care: a pilot randomised controlled trial. Brit J Gen Pract 2013, 63(606):26-27.
    • 22. Dirven JAM, Tange HJ, Muris JWM, van Haaren KMA, Vink G, van Schayck OCP. Early detection of COPD in general practice: patient or practice managed? A randomised controlled trial of two strategies in different socioeconomic environments. Prim Care Respir J 2013, 22(3): 331-337
    • 23. Van den Boom G, van Schayck CP, Rutten-van Molken MPM et al. Active detection of Chronic Obstructive Pulmonary Disease and Asthma in the general population. AJRCCM 1998, 158:1730- 8.
    • 24. Van den Boom G, Rutten-van Molken MPM, Folgering H, van Weel C, van Schayck CP. The economic effects of screening for obstructive airway disease: an economic analysis of the DIMCA program. Prev Med 2000, 30:302-8.
    • 25. Raluy-Callado M, Lambrelli D, MacLachlan S, Khalid JM. Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013. International Journal of COPD 2015:10 925-937
    • 26. Sestini P, Renzoni E, Robinson S, Poole P, Ram FSF. Short-acting beta2-agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD001495. DOI: 10.1002/14651858.CD001495
    • 27. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD010844. DOI: 10.1002/14651858.CD010844.pub2.
    • 28. Zwerink M, Brusse-Keizer M, van der Valk PDLPM, et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 3. Art.No.: CD002990. DOI: 10.1002/14651858.CD002990.pub3.
    • 29. Godtfredsen NS, Lam TH, Hansel TT et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J 2008; 32: 844-853. DOI: 10.1183/09031936.00160007
    • 30. Poole P, Chacko EE, Wood-Baker R, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD002733. DOI: 10.1002/14651858.CD002733.pub2.
    • 31. Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD005305. DOI: 10.1002/14651858.CD005305.pub3.
    • 32. Guirguis-Blake JM, Senger CA, Webber EM, Mularski RA, Whitlock EP. Screening for Chronic Obstructive Pulmonary disease. Evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016; 315(13): 1378-93.
    • 33. Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008;12:1046-51.
    • 34. Haroon S, Adab P, Riley RD, Marshall T, Lancashire R, Jordan RE. Predicting risk of COPD in primary care: development and validation of a clinical risk score. BMJ Open Resp Res2015;2:e000060 doi:10.1136/bmjresp-2014-000060
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok